Health Professional Events – Melanoma Research Victoria https://melanomaresearchvic.com.au Mon, 21 Jan 2019 08:03:30 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Health Professional Events – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Physicians’ Education Resource ® to Host 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies ® https://melanomaresearchvic.com.au/physicians-education-resource-to-host-15th-annual-international-symposium-on-melanoma-and-other-cutaneous-malignancies Thu, 10 Jan 2019 21:00:39 +0000 https://melanomaresearchvic.com.au/?p=12701 Source: Business Wire, January 2019 “We are looking forward to hosting our International Symposium on Melanoma and Other Cutaneous Malignancies® once again in New York City,” said Phil Talamo, president of PER.® “Now in its 15th year, the symposium continues to provide physicians with the tools they need to personalize care for every patient they treat with […]

The post Physicians’ Education Resource ® to Host 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies ® appeared first on Melanoma Research Victoria.

]]>
Source: Business Wire, January 2019

“We are looking forward to hosting our International Symposium on Melanoma and Other Cutaneous Malignancies® once again in New York City,” said Phil Talamo, president of PER.® “Now in its 15th year, the symposium continues to provide physicians with the tools they need to personalize care for every patient they treat with skin and other cutaneous including some very exciting data in the adjuvant setting.”

Throughout the international conference, world-renowned melanoma experts Hamid and Weber, along with distinguished skin cancer specialists, will host several sessions covering topics such as current advances in immunotherapy and targeted therapies, the benefits of regional therapy, how to use predictive and prognostic modeling and how to manage treatment-related adverse events associated with emerging strategies. This symposium will also feature a Medical Crossfire®, in which the expert panel will address attendees’ questions and participate in a rigorous debate on pressing issues faced by the skin cancer treatment community.

This highly interactive symposium will also feature a special presentation, “We Are What We Eat: How the Microbiome Influences Responses to Immunotherapy in Cancer,” by Thomas F. Gajewski, M.D., Ph.D., AbbVie Foundation professor of cancer immunotherapy at University of Chicago Medicine. Gajewski investigates and develops new treatments for patients with melanoma. He also serves as an editor for Cancer Research and the Journal for Immunotherapy of Cancer.

read the original full article

The post Physicians’ Education Resource ® to Host 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies ® appeared first on Melanoma Research Victoria.

]]>
The Australasian Melanoma Conference 2016 https://melanomaresearchvic.com.au/australasian-melanoma-conference-2016 Tue, 15 Mar 2016 09:12:57 +0000 http://melbournemelanomaproject.com/?p=6368 Hosted by Melanoma Institute Australia 28 – 29 October 2016, Sofitel Wentworth Hotel, Sydney Welcome Invitation Dear Colleagues, On behalf of the Organising Committee, it is with great pleasure that I invite you to attend The Australasian Melanoma Conference in Sydney this year. This conference will bring together melanoma researchers and clinicians to showcase current […]

The post The Australasian Melanoma Conference 2016 appeared first on Melanoma Research Victoria.

]]>
Hosted by Melanoma Institute Australia

28 – 29 October 2016, Sofitel Wentworth Hotel, Sydney

Welcome Invitation

Dear Colleagues,
On behalf of the Organising Committee, it is with great pleasure that I invite you to attend The Australasian Melanoma Conference in Sydney this year. This conference will bring together melanoma researchers and clinicians to showcase current practice and research innovation and partnerships for better patient outcomes.
In this exciting era of revolutionary melanoma treatment, this conference will be highly relevant to physicians, researchers and nurses. It is also an opportunity to build strong Australasian collaboration by facilitating the exchange of information and stimulating cooperation.
I very much look forward to seeing you to Sydney in October.

Robyn Saw
Conference Chair

Express your interest

The post The Australasian Melanoma Conference 2016 appeared first on Melanoma Research Victoria.

]]>
Melanoma March 2016 is launched https://melanomaresearchvic.com.au/melanoma-march-2016-is-launched Sun, 21 Feb 2016 11:30:14 +0000 http://melbournemelanomaproject.com/?p=6305 Melanoma Institute Australia (MIA) officially launched the 2016 ‘Melanoma March’ initiative in Sydney today. The launch event held at the Sofitel Sydney Wentworth revealed plans for the new project that will receive funds from this year’s Melanoma March campaign. Channel 7’s Dr. Andrew Rochford hosted the event, with MIA”s new CEO Carole Renouf helping to […]

The post Melanoma March 2016 is launched appeared first on Melanoma Research Victoria.

]]>
Source: Melbourne Melanoma Institute, February 2016

Melanoma Institute Australia (MIA) officially launched the 2016 ‘Melanoma March’ initiative in Sydney today.

The launch event held at the Sofitel Sydney Wentworth revealed plans for the new project that will receive funds from this year’s Melanoma March campaign. Channel 7’s Dr. Andrew Rochford hosted the event, with MIA”s new CEO Carole Renouf helping to get the campaign off to a flying start. Melanoma patient and author of Dear Melanoma Emma Betts also spoke passionately about the importance of research.

Professor Graham Mann, Research Director at MIA, explained how the Melanoma March campaign provides critical funding for an ambitious new project that will ultimately transform the way patients are treated by shining a research light on melanoma care.

Participating melanoma centres around the country will link databases, for the first time bringing together the key information about the treatment of their patients on a national scale. At present melanoma is only recorded by national cancer registries at the time it is initially diagnosed. Data suitable for research about the patients’ treatment and progress is currently only collected in a few specialist centres. This project seeks to expand this substantially and facilitate the appropriate combination of this invaluable information to provided new insights into treatment responses, especially with the less common forms of melanoma where our aggregated national experience will be so informative.

read the full original article

The post Melanoma March 2016 is launched appeared first on Melanoma Research Victoria.

]]>
The Australasian Melanoma Conference 2016 28 – 29 October 2016, https://melanomaresearchvic.com.au/the-australasian-melanoma-conference-2016-28-29-october-2016 Thu, 18 Feb 2016 10:28:58 +0000 http://melbournemelanomaproject.com/?p=6277 On behalf of the Organising Committee, we are pleased to invite you to attend The Australasian Melanoma Conference 2016, hosted by Melanoma Institute Australia. Registrations and abstract submissions open in March 2016 for this two day meeting on Friday 28 and Saturday 29 October 2016. Visit www.melanoma2016.com.au to register your interest.

The post The Australasian Melanoma Conference 2016 28 – 29 October 2016, appeared first on Melanoma Research Victoria.

]]>
SAVE THE DATE

On behalf of the Organising Committee, we are pleased to invite you to attend The Australasian Melanoma Conference 2016, hosted by Melanoma Institute Australia.

Registrations and abstract submissions open in March 2016 for this two day meeting on Friday 28 and Saturday 29 October 2016.

Visit www.melanoma2016.com.au to register your interest.

The Australasian Melanoma Conference Program has been designed for researchers, primary care and specialist clinicians, nurses and allied health workers interested in any aspect of melanoma treatment, patient care or research.

Keynote Speakers

We are excited to announce two of the keynote speakers for the 2016 Conference.

Dr Vernon K. Sondak, MD
Chair, Department of Cutaneous Oncology, Director of Surgical Education at Moffitt Cancer Center, Tampa, Florida
and
Professor of Surgery
University of South Florida, Morsani College of Medicine, Tampa, Florida

Dr Jennifer Wargo, MD, MMSc
Associate Professor, Department of Surgical Oncology and Department of Genomic Medicine,
The University of Texas MD Anderson Cancer Center, Houston, Texas

More information about the program and keynote speakers will be announced soon.

Venue

The Conference will be held at Sofitel Wentworth Sydney Hotel, located in the heart of the Sydney CBD. Key transport links, shopping and dining options and stunning Sydney landmarks are only a short stroll away.

Sponsorship and Exhibitor Opportunities

We invite your organisation to participate as a valued sponsor or exhibitor. Along with the variety of different sponsorship and advertising options available, the industry exhibition provides an excellent platform to network with an audience of more than 300 melanoma clinicians and researchers and allied health professionals.

For more information contact our
Sponsorship and Exhibitions Account
Manager on +61 2 9265 0700 or email sponsorship@arinex.com.au.

 

Melanoma 2016 Conference Managers
Arinex Pty Ltd
Level 10, 51 Druitt Street
Sydney, NSW, Australia
Tel: +61 2 9265 0700
Fax: +61 2 9267 5443
Email: melanoma2016@arinex.com.au

The post The Australasian Melanoma Conference 2016 28 – 29 October 2016, appeared first on Melanoma Research Victoria.

]]>
ANZMTG & MRINZ Research Symposium Flyer & Draft Agenda https://melanomaresearchvic.com.au/anzmtg-mrinz-research-symposium-flyer-draft-agenda Wed, 12 Aug 2015 11:16:51 +0000 http://melbournemelanomaproject.com/?p=5430 The Inaugural Research Symposium will be on Thursday 5th November 2015 Location The Crystal Ballroom The Langham Hotel 83 Symonds St, Grafton, Auckland 1010 To register email:info@melanomaresearch.org.nz website: https://www.anzmtg.org/

The post ANZMTG & MRINZ Research Symposium Flyer & Draft Agenda appeared first on Melanoma Research Victoria.

]]>
The Inaugural Research Symposium will be on Thursday 5th November 2015

Location

The Crystal Ballroom
The Langham Hotel
83 Symonds St, Grafton,
Auckland 1010

The post ANZMTG & MRINZ Research Symposium Flyer & Draft Agenda appeared first on Melanoma Research Victoria.

]]>
Your Funds Are Helping Us Tackle Skin Cancer and Melanoma https://melanomaresearchvic.com.au/your-funds-are-helping-us-tackle-skin-cancer-and-melanoma Fri, 08 May 2015 13:31:45 +0000 http://melbournemelanomaproject.com/?p=4870 Over 1,200 people participated in the March Against Melanoma™ last month at The Tan in Melbourne. Your efforts raised over $66,000 which is being used for melanoma research.

The post Your Funds Are Helping Us Tackle Skin Cancer and Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: SkinandCancer Foundation Inc, April 2015

Over 1,200 people participated in the March Against Melanoma™ last month at The Tan in Melbourne. Your efforts raised over $66,000 which is being used for melanoma research.

Doctor Victoria Mar, a consultant dermatologist, is leading our research into melanoma.

Dr Victoria Mar'

Dr Victoria Mar’s melanoma research has been supported by the 2015 March Against Melanoma.
Source: Skin and Cancer Foundation Inc

Dr Mar has a keen interest in early detection and management of cutaneous melanoma. She is currently working to assist in improving diagnosis and mapping of lentigo maligna (a melanoma that consists of malignant cells but does not show invasive growth). Common in Australia, occurring on chronically sun damaged skin, lentigo maligna poses surgical challenges, as it predominantly occurs on the face. Dr Mar’s research involves using a hand-held confocal machine to map the extent of the lentigo maligna more accurately and improve patient outcomes.

Funds raised at the March Against Melanoma™ are also going towards Dr Mar’s research into why patients who develop one melanoma are at an increased risk of developing a second or third melanoma. Dr Mar is particularly interested in studying the mutational changes that occur in individual melanomas within the same patient and what this might be able to reveal about the genetics of melanoma risk, as well as early melanoma development.

Dr Mar has previously shown that melanomas with specific mutations are more likely to spread to lymph nodes and cause death, despite having otherwise favourable histological features (the microscopic make up of their cells).

Your support at the March Against Melanoma™ will assist Dr Mar in following a large cohort of patients with known mutations over time to learn whether the types of mutations present in the tumor determine how it will spread (i.e. via the lymph nodes or via the blood, and the different organs which might be affected).

This research has the potential to have substantial impact on patient outcomes.

Dr Mar’s work has been recognised and awarded throughout Australia. Last year she was presented the F&E Bauer Foundation Prize for her presentation at the 2014 Annual Scientific Meeting of the Australian College of Dermatologists and she was also recently appointed to the Executive Committee of the Australia and New Zealand Melanoma Trials Group.

Often when we fundraise for a charity or organisation we never learn where our dollars have been used but each and every person who donated their time, hard work and support at our March Against Melanoma™ can be assured their money is being well-spent with Dr Mar’s valuable research.

read original article

The post Your Funds Are Helping Us Tackle Skin Cancer and Melanoma appeared first on Melanoma Research Victoria.

]]>
Novel Rose Bengal Formulation Obliterates Lesions in Patients with Deadliest of Melanomas https://melanomaresearchvic.com.au/novel-rose-bengal-formulation-obliterates-lesions-patients-deadliest-melanomas Thu, 09 Oct 2014 11:15:20 +0000 http://melbournemelanomaproject.com/?p=3613 Data Presented at the European Society for Medical Oncology Congress in Spain Shows New Approach offers Overall Response Rate of 71%

The post Novel Rose Bengal Formulation Obliterates Lesions in Patients with Deadliest of Melanomas appeared first on Melanoma Research Victoria.

]]>
Source: Newswise, Spetember 2014

Data Presented at the European Society for Medical Oncology Congress in Spain Shows New Approach offers Overall Response Rate of 71%

A formulation of the dye, rose bengal, which has been around for more than a century, has recently been shown to have promise in patients with cutaneous melanoma, one of the deadliest forms of the disease. Originally used as a coal tar–derived wool dye, rose bengal has most commonly been used as a stain for detecting ocular conditions starting in the 1930s.

This mild-mannered stain, however, turns into a cancer killing superhero when properly prepared and injected into melanoma lesions. Furthermore, the drug has been shown to create what experts call mediated tumor-specific immune response to cancer. Completed Phase II data was recently presented at the European Society for Medical Oncology 2014 Congress in Madrid that detailed the safety and efficacy of intralesional (IL) treatment of refractory cutaneous melanoma with rose bengal disodium. The data came from an 80 patient international, multicenter, single arm phase II trial.

Sanjiv S. Agarwala, MD, an internationally recognized investigator in the field of melanoma and immunotherapy and chief of medical oncology and hematology for St. Luke’s University Hospital & Health Network, based in Bethlehem, Pa, titled his abstract “Subgroup Efficacy in Patients Receiving Intralesional Rose Bengal to All Existing Melanoma in Phase II Study PV-10-MM-02.”

Dr. Agarwala found patients refractory to a median of 6 previous interventions with 6.3cm median sum lesion diameter in biopsy-confirmed melanoma received PV-10 – the 10% rose bengal solution currently produced and being investigated by Provectus Biopharmaceuticals. Dr. Agarwala has published a variety of therapeutic approaches to melanoma and has led promising clinical trials in immunotherapy and targeted therapy of melanoma. He co-authored the book “Melanoma: Translational Research and Emerging Therapies” to help bridge the gap between research and clinical approaches to melanoma therapy.

Dr. Agarwala detailed in his presentation of the secondary effects of PV-10 to the cancerous lesions. “Although the primary ablative effect is responsible for complete response in injected lesions, durability of response and bystander response observed in this study implicate an immunologic mechanism of action secondary to ablation,” states Dr. Agarwala. Dr. Agarwala’s team started by injected the rose bengal solution into as many as 20 cutaneous and subcutaneous lesions up to 4 times over a 16-week period with patients followed for 52 weeks. The team found that they achieved the best overall response rate (BORR) assessed in up to 10 injected target lesions.

Overall, the team at St. Luke’s found that PV-10 was well tolerated and 41 of 80 patients met the primary endpoint of objective response (Complete Response + Partial Response) in their injected target lesions (51% ORR CI 40-63%, 26% CR). In the subgroup of 28 patients who received PV-10 into all existing melanoma lesions, ORR was 71% (CI 51-87%) with 50% CR (CI 31-69%). In these patients plus 26 other patients with uninjected disease limited to bystanders (i.e., 54 patients in all) CR was achieved in 232 of 363 injected lesions (64% CR): 121 lesions required a single injection for CR, 84 required 2 injections, 22 required 3 injections and 5 required 4 injections. Additionally, 10 of 28 uninjected bystander lesions achieved complete response.

Eric Wachter, PhD and Chief Technology Officer of Provectus, said, “We are very pleased to share the patient-level PFS data at ESMO that defined our design parameters for the upcoming phase 3 trial. These study results demonstrate the potential of an intralesional approach to delay progression while alleviating symptoms of locally advanced melanoma.”

Wachter continued, “We are looking forward to initiation of the phase 3 trial and have assembled an experienced multi-disciplinary team to help us execute this important study. For example, we are thrilled to collaborate with ERT, Inc., experts in quantifying patient reported outcomes for pivotal oncology trials, and expect this collaboration to help place Provectus at the forefront in the study of cutaneous symptoms of locally advanced melanoma.”

Wachter concluded, “The data presented at ESMO were fundamental in allowing us be in a position to commence pivotal testing of PV-10 in locally advanced melanoma patients. Furthermore, understanding the bystander effect is critical to rational combination of PV-10 with systemic drugs in patients with significant disease inaccessible to intralesional injection, and we look forward to seeing additional data on this important topic in coming months.”

The abstract can be accessed via the following link: http://www.pvct.com/publications/Provectus-ESMO-2014-09-28.pdf

 

=3&search[sort]=date+desc&search[section]=10&search[has_multimedia]” window=”yes”]read original article

The post Novel Rose Bengal Formulation Obliterates Lesions in Patients with Deadliest of Melanomas appeared first on Melanoma Research Victoria.

]]>
Professor Grant McArthur to drive even better patient outcomes as inaugural Lorenzo Galli Chair in Melanoma and Skin Cancers https://melanomaresearchvic.com.au/professor-grant-mcarthur-drive-even-better-patient-outcomes-inaugural-lorenzo-galli-chair-melanoma-skin-cancers Mon, 25 Aug 2014 21:00:17 +0000 http://melbournemelanomaproject.com/?p=3345 The Peter MacCallum Cancer Centre’s Professor Grant McArthur will spearhead a new era of Victorian melanoma and skin cancer research following his appointment as the inaugural Lorenzo Galli Chair in Melanoma and Skin Cancers.

The post Professor Grant McArthur to drive even better patient outcomes as inaugural Lorenzo Galli Chair in Melanoma and Skin Cancers appeared first on Melanoma Research Victoria.

]]>
Source: Peter Mac, August 2014
Peter MacCallum Cancer Centre

source: Peter Mac

The Peter MacCallum Cancer Centre’s Professor Grant McArthur will spearhead a new era of Victorian melanoma and skin cancer research following his appointment as the inaugural Lorenzo Galli Chair in Melanoma and Skin Cancers.

Professor McArthur: Chair, Melanoma and Skin Service and Co-Head, Cancer Therapeutics Program at Peter Mac (pictured, second from right) was selected from an international field for the position, established at The University of Melbourne through a generous $5m gift from Mrs Pamela Galli (pictured, second from left), in honour of her husband, Mr Lorenzo Galli, who died as a result of melanoma.

Ms Dale Fisher: Chief Executive (pictured, left) says Mrs Galli’s generous gift will enable Professor McArthur, to guide, via a formal structure, the efforts of some of the best and brightest minds in skin cancers and melanoma in the state.

‘While we have made great advances in skin cancer and melanoma research, far too many people succumb to their disease — we know the best plan of attack is to work together and this appointment will enable Professor McArthur to strategically focus the efforts of skin cancer and melanoma clinicians and researchers from across the seven organisations that comprise the Victorian Comprehensive Cancer Centre alliance.’

Professor McArthur says melanoma and skin cancers are biologically complex and remain a large health burden, requiring a concerted response to improve outcomes for patients.

‘I am proud to be the inaugural Chair in Melanoma and Skin Cancers and this gift from Mrs Galli will allow us to build stronger research programs, teach the next generation of doctors and refine better treatments to accelerate the survival rates of these insidious diseases, for the benefit of people across the globe.’

Also pictured, right, is Professor Stephen Smith: Dean of the Faculty of Medicine, Dentistry and Health Sciences at The University of Melbourne.

Read Original Article

The post Professor Grant McArthur to drive even better patient outcomes as inaugural Lorenzo Galli Chair in Melanoma and Skin Cancers appeared first on Melanoma Research Victoria.

]]>
2014 Conferences https://melanomaresearchvic.com.au/2014-conferences Wed, 18 Jun 2014 09:51:50 +0000 http://melbournemelanomaproject.com/?p=3016 June 26 – 27, 4th European Post-Chicago Melanoma / Skin Cancer Meeting, Munich, Germany http://melanomaglobal2014.org/ July 6 – 11, European Society for Plastic, Reconstructive and Aesthetic Surgery Congress, Edinburgh, Scotland http://www.espras2014.org/ August 6 – 8, Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting, Sydney, Australia https://www.moga.org.au/ September 3 – 6, 15th World Congress on […]

The post 2014 Conferences appeared first on Melanoma Research Victoria.

]]>
June

26 – 27, 4th European Post-Chicago Melanoma / Skin Cancer Meeting, Munich, Germany

http://melanomaglobal2014.org/

July

6 – 11, European Society for Plastic, Reconstructive and Aesthetic Surgery Congress, Edinburgh, Scotland

http://www.espras2014.org/

August

6 – 8, Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting, Sydney, Australia

https://www.moga.org.au/

September

3 – 6, 15th World Congress on cancers of the skin, Edinburgh, Scotland

http://www.wccs2014.org/

4 – 5, 10th Nordic Melanoma Group Meeting, Turku, Finland

http://www.melanoma.dk/

4 – 7, Combined Annual Conference – Imaging and Radiation in Personalised Medicine, Melbourne, Australia

http://www.csm2014.com/

14-17, American Society for Radiation Oncology 56th Annual meeting, San Francisco, USA

http://www.astro.org/Meetings-and-Events/Future-Annual-Meetings.aspx

14 – 20, Australian and Asia Pacific Clinical Oncology Research Development (ACORD) workshop, Sunshine Coast, Australia

http://www.acord.org.au/

18-21, 1st Euro-Asian Melanoma Congress, Sarajevo, Bosnia and Herzegovina

http://www.eurolink-tours.co.uk/Dermatology_congress/1st-euro-asian-melanoma-congress-1890.html

26 – 30, European Society for Medical Oncology, Madrid, Spain

http://www.esmo.org/Conferences/ESMO-2014-Congress

October

2 – 4, Neurosurgical Society of Australasia Annual Scientific Meeting, Sydney, Australia

http://www.nsa.org.au/events/category/annual-scientific-meeting

9, ANZMTG Annual Scientific Research Meeting, Perth, Australia

http://www.anzmtg.org

9 – 11, SKMRC 2nd National Melanoma Conference, Perth, Australia

http://www.skmrc.org.au/

November

13 – 16, Society for Melanoma Research 2014 International Congress, Zurich, Switzerland

http://www.melanomacongress.com/

16 – 19, Australian Health and Medical Research Congress, Melbourne, Australia

http://www.ahmrcongress.org.au/

December

3 – 6, World Cancer Congress, Melbourne, Australia

http://www.worldcancercongress.org/melbourne-2014

4-6, Clinical Oncological Society of Australia 41st Annual Scientific Meeting, Melbourne, Australia

https://www.cosa.org.au/events/annual-scientific-meetings.aspx

 

The post 2014 Conferences appeared first on Melanoma Research Victoria.

]]>
Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study https://melanomaresearchvic.com.au/novel-immunotherapeutic-safe-effective-early-phase-melanoma-study Thu, 24 Apr 2014 12:50:33 +0000 http://melbournemelanomaproject.com/?p=2820 A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma, according to results from a phase I clinical trial presented at the 2014 AACR Annual Meeting.

The post Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, April 2014

A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma, according to results from a phase I clinical trial presented at the 2014 AACR Annual Meeting.

“The drug is well tolerated in advanced melanoma patients, and we have seen clinical responses in some of them,” Mark Middleton, MD, PhD, lead author on the study and professor of experimental cancer medicine at the University of Oxford, said in a statement. “The one aspect that did surprise us is the extent of tumor inflammation that is possible to achieve from just a single dose of the drug, because we thought it might take several weeks to get going.”

T cell (grey) killing a tumour cell (yellow)

T cell (grey) killing a tumour cell (yellow)
Source:OncLive

The maximum tolerated dose (MTD) was determined to be 600ng/kg, with doses ranging from 5ng/kg to 900ng/kg explored in the study. Four patients received the highest dose, of which 50% developed grade 3 hypotension. In general, side effects included rash, fever, skin inflammation, and tumor flare. In 16 patients who received doses greater than 135ng/kg, 13% experienced a partial response (PR) by RECIST criteria that lasted longer than 9 months.

IMCgp100 is comprised of an enhanced T cell receptor fused to an anti-CD3 antibody fragment. The T cell receptor is engineered to be specific to gp100, which presents in the context of HLA-A2 on the surface of melanoma cells. Once joined to the antigen, the antibody fragment recruits and activates T cells to elicit an anti-tumor response.

In the trial, 31 patients with stage IV or stage III unresectable melanoma who tested positive for HLA-A2 were divided into 8 cohorts to receive IMCgp100. Following the initial dose, patients were followed for 30 days. Patients who tolerated the first dose received weekly doses of IMCgp100 for 6 cycles. Doses were escalated until criteria for MTD were reached.

The median age of patients was 61. In total, 60% of patients (n=19) received prior systemic treatment with DTIC (n=9), ipilimumab (n=2), vemurafenib (n=1), or one or more experimental therapies (n=7). Patients with symptomatic and unstable brain metastases requiring steroids and those eligible for vemurafenib were excluded from the trial.

Four patients achieve a PR by investigator assessment: 1 was observed following the first dose and 2 continued for more than 9 months of treatment. Additionally, 1 patient experienced stable disease for more than 10 months. Responses were seen in metastatic lesions in patients’ lungs, lymphatic systems, and various soft tissues.

The most common adverse events observed were transient grade 3 pruritic rash, initially seen at dose level 45ng/kg, and grade 2 pyrexia. Patients with cutaneous or subcutaneous disease experienced tumor flare. Adverse events were consistent with the mechanism of action of IMCgp100, the researchers noted.

“We’re still trying to understand how do we best deal with gp100 as a potential target, but certainly, additional research into new immune therapies is necessary,” Michael A. Postow, MD, an attending physician in the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center, said in an interview. “Until we have a 100% cure for this disease, we’re going to continue to work.”

In October 2013, Immunocore Limited, the company developing IMCgp100, announced the initiation of a phase IIa trial to optimize the dosing regimen and maximize the efficacy of the agent. This study will administer weekly IMCgp100 at the MTD established in the phase I investigation.

“Although we are encouraged by the clinical activity observed, all of the available scientific and clinical data suggest that it should be possible to increase the level of clinical activity with an improved dosing regimen,” Middleton said. “We have initiated a phase IIa trial, in which we are testing a weekly dosing arm, building on the clinical data generated to date, and a second arm exploring a more intensive regimen that should maximize the activity of the drug.”

In the summer of 2013, Immunocore reached partnership agreements with Genentech and GlaxoSmithKline to discover, develop, and commercialize therapies against multiple targets using Immunocore’s proprietary T Cell Receptor technology platform known as ImmTAC. Each partnership could result in over $330 million in development and commercial milestones plus royalties.

Read Original Article

The post Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study appeared first on Melanoma Research Victoria.

]]>